The significance of microthrombosis and fgl2 in no-reflow phenomenon of rats with acute myocardial ischemia/reperfusion

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 1, 2013, Pages 19-28

  Shao, Liang ^a   Wu, Daying ^a   Zhang, Ping ^a   Li, Wenzhu ^a   Wang, Jue ^a   Su, Guanhua ^a   Liao, Yuhua ^a   Wang, Zhaohui ^a   Liu, Kun ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

acute myocardial ischemia reperfusion; fibrinogen like protein 2; microthrombosis; no reflow

Indexed keywords

FIBRINOGEN; FIBRINOGEN LIKE PROTEIN 2; THIOFLAVINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; HEART HEMODYNAMICS; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; MALE; MICROCIRCULATION; MICROTHROMBUS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ACUTE DISEASE; ANIMALS; CORONARY THROMBOSIS; FIBRINOGEN; GENE EXPRESSION REGULATION; HEMODYNAMICS; LEUKOCYTES, MONONUCLEAR; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NO-REFLOW PHENOMENON; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84871536298     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029612437577     Document Type: Article

References (28)

1. Hoit BD, Gilpin EA, Henning H, et al. Myocardial infarction in young patients: an analysis by age subsets. Circulation. 1986 ; 74 (4). 712-721
2. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Circulation. 1995 ; 91 (6). 1659-1668
3. Reffelmann T, Kloner RA. The "no-reflow" phenomenon: basic science and clinical correlates. Heart. 2002 ; 87 (2). 162-168
4. Okamura A, Ito H, Iwakura K, et al. Detection of embolic particles with the Doppler guide wire during coronary intervention in patients with acute myocardial infarction: efficacy of distal protection device. J Am Coll Cardiol. 2005 ; 45 (2). 212-215
5. Verma S, Fedak PW, Weisel RD, et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation. 2002 ; 105 (20). 2332-2336
6. Ndrepepa G, Tiroch K. Fusaro M, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010 ; 55 (21). 2383-2389
7. Resnic FS, Wainstein M, Lee MK, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J. 2003 ; 145 (1). 42-46
8. Granger DN. Ischemia-reperfusion: mechanisms of microvascular dys-function and the influence of risk factors for cardiovascular disease. Microcirculation. 1999 ; 6 (3). 167-178
9. Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg. 1999 ; 68 (5). 1905-1912
10. Agati L. Microvascular integrity after reperfusion therapy. Am Heart J. 1999 ; 138 (2 pt 2). S76 - S78
11. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974 ; 54 (6). 1496-1508
12. Yuwaraj S, Ding J, Liu M, Marsden PA, Levy GA. Genomic characterization, localization, and functional expression of FGL2, the human gene encoding fibroleukin: a novel human procoagulant. Genomics. 2001 ; 71 (3). 330-338
13. Zhu CL, Yan WM, Zhu F, et al. Fibrinogen-like protein 2 fibroleukin expressionand its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B. World J Gastroenterol. 2005 ; 11 (44). 6936-6940
14. Ning Q, Sun Y, Han M, et al. Role of fibrinogen-like protein 2 prothrombinase/fibroleukin in experimental and human allograft rejection. J Immunol. 2005 ; 174 (11). 7403-7411
15. Mendicino M, Liu M, Ghanekar A, et al. Targeted deletion of Fgl-2/fibroleukin in the donor modulates immunologic response and acute vascular rejection in cardiac xenografts. Circulation. 2005 ; 112 (2). 248-256
16. Ghanekar A, Mendicino M, Liu H, et al. Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection. J Immunol. 2004 ; 172 (9). 5693-5701
17. Clark DA, Chaouat G, Arck PC, Mittruecker HW, Lev GA. Cutting edge. Cytokine-dependent abortion in CBA x DBA/2 mice is mediated by the procoagulant fgl2 prothombinase. J Immunol. 1998 ; 160 (2). 545-549
18. Han M, Yan W. Huang Y, et al The Nucleocapsid protein of SARS-CoV induces transcription of hfgl2 prothrombinase gene dependent on C/EBP alpha. J Biochem. 2008 ; 144 (1). 51-62
19. Shalev I, Liu H, Koscik C, et al. Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis. J Immunol. 2008 ; 180 (1). 249-260
20. Reffelmann T, Hale SL, Li G, Kloner RA. Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2002 ; 282 (2). H766 - H772
21. Reffelmann T, Hale SL, Dow JS, Kloner RA. No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion. Circulation. 2003 ; 108 (23). 2911-2917
22. Michael LH, Entman ML, Hartley CJ, et al. Myocardial ischemia and reperfusion: a murine model. Am J Physiol. 1995 ; 269 (6 pt 2). H2147 - H2154
23. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J. 2001 ; 22 (9). 729-739
24. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002 ; 105 (5). 656-662
25. Herrmann J. Peri-procedural myocardial injury: 2005 update. Eur Heart J. 2005 ; 26 (23). 2493-2519
26. Sherman JR, Anwar A, Bret JR, Schreibfeder MM. Distal vessel pullback angiography and pressure gradient measurement: an innovative diagnostic approach to evaluate the no-reflow phenomenon. Cathet Cardiovasc Diagn. 1996 ; 39 (1). 1-6
27. Iwakura K, Ito H, Nishikawa N, et al. Early temporal changes in coronary flow velocity patterns in patients with acute myocardial infarction demonstrating the "no-reflow" phenomenon. Am J Cardiol. 1999 ; 84 (4). 415-419
28. Zabel M, Hohnloser SH, Köster W, et al. Analysis of creatine kinase, CK-MB, myoglobin, and troponin T time-activity curves for early assessment of coronary artery reperfusion after intravenous thrombolysis. Circulation. 1993 ; 87 (5). 1542-1550